Jacobs Levy Equity Management
GYRE icon

Jacobs Levy Equity Management’s Gyre Therapeutics GYRE Stock Holding History

Jacobs Levy Equity Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,195
Closed -$83K – 1065
2021
Q1 		$83K Sell
2,195
-5,869
-73% -$268K ﹤0.01% 997
2020
Q4 		$382K Sell
8,064
-8,586
-52% -$372K ﹤0.01% 885
2020
Q3 		$537K Buy
16,650
+2,927
+21% +$115K 0.01% 776
2020
Q2 		$604K Buy
+13,723
New +$644K 0.01% 759
2014
Q2 		– Sell
-41
Closed -$152K – 864
2014
Q1 		$152K Hold
41
– – ﹤0.01% 839
2013
Q4 		$135K Sell
41
-49
-54% -$193K ﹤0.01% 895
2013
Q3 		$376K Sell
90
-85
-49% -$342K 0.01% 752
2013
Q2 		$587K Buy
+175
New +$666K 0.01% 693

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Jacobs Levy Equity Management's GYRE Position: Q2 2021 in Review

Jacobs Levy Equity Management sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 2,195 shares — an estimated $83K sold.

Jacobs Levy Equity Management first reported a position in GYRE in Q2 2013 and held it in 8 quarters. The position peaked at $604K in Q2 2020. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Jacobs Levy Equity Management reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,195 Gyre Therapeutics shares in Q2 2021, an estimated $83K.
  • Jacobs Levy Equity Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Gyre Therapeutics position peaked at $604K in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.